AnaptysBio, Inc.

AnaptysBio, Inc. is a clinical-stage biotechnology company headquartered in San Diego, California, focused on the discovery, development, and commercialization of innovative antibody-based therapeutic products. The company's mission is to address unmet medical needs in inflammation and immuno-oncology by transforming patient health through novel immunology therapeutics.

Leveraging a proprietary somatic hypermutation (SHM)-based antibody discovery platform, AnaptysBio has developed a pipeline of immune cell modulating antibodies. Key product candidates include rosnilimab, a PD-1 agonist in Phase 2b trials for rheumatoid arthritis and Phase 2 for ulcerative colitis; ANB032, a BTLA agonist in Phase 2b for atopic dermatitis; and ANB033, a CD122 antagonist in Phase 1b for celiac disease and eosinophilic esophagitis. The company has also out-licensed therapeutic antibodies, such as Jemperli (dostarlimab-gxly) to GSK and imsidolimab to Vanda Pharmaceuticals.

In April 2026, AnaptysBio completed the spin-off of its biopharma operations into a new public entity, First Tracks Biotherapeutics. Following this separation, AnaptysBio, Inc. now operates as a royalty management company, exclusively focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with the objective of protecting and returning royalty value to shareholders. Daniel Faga serves as the President and Chief Executive Officer, having been appointed in March 2022.